Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
news icon
Repligen buys French filtration firm Polymem
external link icon
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22.  Tony J. Hunt, President and Chief Executive Officer, will participate in an analyst-led discussion on Tuesday, March 21, at 1:30 p.m. EDT. A live webcast of the presentation will be accessible through the  Investor Relations  section of the Company’s website, and will be available for replay for a limited period of time following the conference event.
About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical
external link icon
Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (“Purolite”), for the development and manufacturing of affinity ligands focused on monoclonal antibodies (“mAb”) and antibody fragments. Repligen entered into an exclusive agreement with Purolite in 2018 for the development and supply of NGL-Impact ® Protein A ligands. This agreement extends our exclusive partnership to 2032 and broadens the scope of the partnership to now include ligands targeting mAb fragments. Tony J. Hunt, President and CEO of Repligen, said, “We are delighted with the progress we have made working with Purolite and now Ecolab to establish the NGL family of Protein A ligands in the marketplace. This extension and product line expansion is well aligned with our Proteins strategy and supports the acceleration in market adoption of the Praesto ® affinity resin portfolio. It provides
external link icon
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 22-23, 2022.  Tony J. Hunt, President & Chief Executive Officer, will participate in a fireside chat on Tuesday, March 22, at 9:45 a.m. EDT.
A live webcast of the presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical
external link icon
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 23-24.  Tony Hunt, President & Chief Executive Officer, will participate in a fireside chat on Wednesday, March 24, at 9:15 a.m. EDT. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing
external link icon
Repligen Announces Conference Call to Report First Quarter of 2012 Financial Results
external link icon
Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
news icon
Repligen Launches the CTech™ SoloVPE® PLUS System
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in complex biological production workflows, from process development scale through cGMP manufacturing.
corporate icon
Viral Vector Manufacturing
Adeno-associated virus (AAV) is the most common viral vector used in gene therapy bioprocessing. Other viral vectors include adenovirus, retrovirus, exosomes, oncolytic virus, and virus-based vaccines.
external link icon
Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich’s Ataxia Preclinical Development Program